FLT3 and acute myeloid leukemia: Due to the upregulation of multiple different signaling genes in FLT3-ITD AML after FLT3 inhibition these treatments are still vulnerable to cytokine-mediated resistance from other factors, also due to the heterogeneity of responses to FLT3 inhibitors in cell lines and patient samples.